* Zevra Therapeutics Inc reported a quarterly adjusted loss of 69 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -40 cents. The mean expectation of eight analysts for the quarter was for a loss of 42 cents per share. Wall Street expected results to range from -50 cents to -36 cents per share.

* Revenue rose 27.6% to $3.70 million from a year ago; analysts expected $4.87 million.

* Zevra Therapeutics Inc's reported EPS for the quarter was a loss of 69 cents​.

* The company reported a quarterly loss of $33.23 million.

* Zevra Therapeutics Inc shares had risen by 29.1% this quarter and gained 36.8% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had fallen by about 2.2% in the last three months.​

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Zevra Therapeutics Inc is $20.50 This summary was machine generated from LSEG data November 12 at 11:28 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 -0.42 -0.69 Missed

Jun. 30 2024 -0.43 -0.48 Missed

Mar. 31 2024 -0.48 -0.40 Beat

Dec. 31 2023 -0.27 -0.40 Missed